Which hedge funds own CBIO? CRESCENT BIOPHARMA INC., Q2 2026 13F holders

25 tracked hedge funds disclosed a position in CBIO (CRESCENT BIOPHARMA INC.) in their Q2 2026 13F filings, worth $254.9m in total. The largest holder by portfolio weight is Fairmount Funds Management LLC at 3.3% of its book. 5 opened a new position this quarter: Stempoint Capital LP, Persistent Asset Partners Ltd, Y-Intercept (Hong Kong) Ltd, Squarepoint Ops LLC. 8 exited: Cannon Global Investment Management, LLC, Verdad Advisers, LP, Deep Track Capital, LP.

25

Holders

Tracked managers whose filing for the quarter reports a long equity position in the security.

5

New this quarter

Holders whose previous filing (at most two quarters earlier) did not report the security.

8

Exited this quarter

Tracked managers whose previous filing reported the security and whose filing for the quarter does not.

$4.8m

Inflow, new holders

Combined value of the positions the new holders reported for the quarter.

$16.5m

Outflow, exits

Combined value the exiting managers reported for the security in their previous filing.

$255m

Combined value

Sum of the holders' reported positions in the security.

2.0%

Share of managers holding

Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.